Objectives: Current treatment options for Clostridium difficile-associated diarrhoea (CDAD) leave a high unmet medical need for new therapies. Cadazolid is a new antibiotic in development for the treatment of CDAD. The objectives of this study were to evaluate its tolerability and pharmacokinetics following single ascending doses (AC-061-101) and multiple ascending doses (AC-061-102).
Introduction
Clostridium difficile, a Gram-positive, anaerobic, spore-forming bacterium, is the most common cause of nosocomial antibioticassociated infectious diarrhoea, frequently reported within the elderly population and resulting in a significant burden on healthcare systems. 1 -6 C. difficile-associated diarrhoea (CDAD) results from the overgrowth in the colon of toxigenic strains of C. difficile, generally as a consequence of a disturbance of the normal protective enteric flora during or after broad-spectrum antibiotic therapies. CDAD manifests as diarrhoea, abdominal pain, fever and leucocytosis in response to the induced intestinal mucosal inflammation (colitis). The latter can degenerate, in the most severe cases, into pseudomembranous colitis, toxic megacolon, bowel perforation, sepsis and toxic shock. 1 Two C. difficile toxins (toxin A and B) are overexpressed in hypervirulent bacterial isolates (such as NAP1/ 027/BI strains) and are considered to be the main virulence factors for the establishment of infection. 2 -4 When oral therapy is possible, European guidelines for the antimicrobial therapy of CDAD indicate as first-choice antimicrobial regimens against moderate to severe CDAD, 10 days of three times daily metronidazole or four times daily vancomycin. However, these standard regimens have been associated with treatment failures or recurrence of infection in 20% -45% of the patients. 3, 6, 7 Additional concerns associated with current treatments are their broad-spectrum activity, which could lead to a more extreme imbalance of the gut microflora, and the potential selection of vancomycin-resistant enterococci when vancomycin is administered. 6 -8 These considerations, and the observed increase in community and nosocomial CDAD, prompt the growing medical need for novel and specific therapies effective against multiple recurrences and severe CDAD. The main features of novel antimicrobial candidates against CDAD are a narrow antimicrobial spectrum, bactericidal activity against C. difficile and minimal systemic exposure after oral administration. 1, 5, 6 Fidaxomicin is a novel RNA polymerase inhibitor that fulfils those features and was recently approved for the treatment of CDAD. In clinical studies in patients with CDAD, fidaxomicin has shown lower recurrence rates and higher global cure rates than standard therapies. 9 -11 However, the treatment options for CDAD remain limited, leaving a high medical need for therapies that give improved sustained cure rates. 1, 3, 6 Cadazolid ( Figure 1 ) is a new oxazolidinone antibiotic; it is moderately lipophilic (log D¼ 1.2), acidic (pKa¼6.0) and has very poor aqueous solubility ( 150 ng/mL). Cadazolid's mechanism of action involves the inhibition of bacterial protein synthesis. 12 -14 In pre-clinical studies, cadazolid showed potent and bactericidal in vitro activity against C. difficile and a low propensity for resistance development. 12, 13 Activity was shown against all 209 strains of C. difficile tested, with a narrow MIC range of 0.06 -0.5 mg/L and an MIC 90 of 0.25 mg/L.
14 Importantly, potent in vitro inhibition of C. difficile toxin production and spore formation, superior to that of vancomycin and metronidazole, was also demonstrated. 13 In hamster and mouse models of CDAD, cadazolid was effective in preventing diarrhoea-related deaths in a dose-dependent manner, similarly to vancomycin. 15 In line with its physico-chemical properties, systemic exposure to cadazolid was negligible following oral administration in Wistar rats and beagle dogs, with most of the drug excreted unchanged in the faeces.
The excellent pre-clinical pharmacology and safety profiles of cadazolid supported its further clinical development. Here, we describe the results of the first trial in humans, in the form of a single ascending dose (SAD) study (AC-061-101), as well as the results of a multiple ascending dose (MAD) study (AC-061-102) (http://trials. actelion.com/asp/Trial_Registry/ListStudy.asp?PN=ACT-179811). The overall objectives of the studies were to determine the safety, tolerability and pharmacokinetic (PK) profile of cadazolid following single-and multiple-dose administration in healthy male subjects.
Methods

Study drug
The study drugs were cadazolid (30, 100 and 500 mg) and placebo, provided as powder for suspension in amber bottles. For reconstituting the study drug, 25 mL of mineral water per bottle was used. The placebo formulation was identical in appearance to the active drug.
Study population
The study population consisted of non-smoking healthy male subjects of any ethnic origin aged between 45 and 65 years, with a body mass index between 18 and 32 kg/m 2 . For recruitment, the subjects underwent standard safety assessments during a screening visit. Subjects who reported the use of any antibiotic within the previous 3 months were excluded from the study. Consumption of grapefruit or grapefruit juice, coffee and caffeine-or xanthine-containing beverages was not permitted during the studies. Written informed consent was obtained from each individual participating in the study prior to any study procedure.
Study design
The studies were conducted in full conformance with the principles of the Declaration of Helsinki and with the laws and regulations of Germany, where the research studies were conducted. The protocol and any material provided to the subject was reviewed and approved by an independent ethics committee (Ethik-Kommission-Landesä rztekammer Baden-Wü rttemberg, Stuttgart, Germany) before the study was started.
The SAD and MAD studies were double-blind, randomized, placebocontrolled, phase I dose-escalation studies. Subjects who were considered suitable after the screening examination were admitted to the site 1 day before the start of treatment and were assigned a randomization code number. This ensured blinding during the conduct of the study and anonymity of the subject.
The SAD study consisted of five treatment groups (30 mg, 100 mg, 300 mg, 1000 mg and 3000 mg) of eight subjects each. In each dose group, six subjects received active medication and two received placebo. After administration of the study drug on the morning of day 1, the subjects remained under observation at the study site for 5 days. On the morning of day 6, an end-of-study visit was performed, and subjects were discharged from the study site. All subjects received a single oral dose of the study drug in the fasted state, with the exception of subjects in the 300 mg dose group, who received a second single oral dose of the same study drug after a washout period of 14 days and within 10 min of completing a high-fat, high-calorie breakfast (approximately 150 kcal as protein, 250 kcal as carbohydrate and 500-600 kcal as fat).
The MAD study consisted of three dose groups (300 mg, 1000 mg and 3000 mg) of eight subjects each (six receiving active drug and two receiving placebo). The treatment was given orally for 10 days twice daily (days 1 -9), except on day 10 when only the morning dose was given. The morning doses were administered in the fasted state and in the evening (12 h later) at least 1 h after the evening meal. Subjects resided at the study site during the treatment until the morning of day 15 (120 h after last dose), when they were discharged from the clinic after an end-of-study visit.
Safety and tolerability evaluation
Records of all adverse events (AEs), vital signs, ECG and laboratory parameters were kept during the subject's stay in the clinic. Changes from baseline (measured on day 1, before dosing) of vital signs, ECG and clinical laboratory parameters were determined and evaluated for clinical relevance. Cadazolid tolerability and pharmacokinetics in healthy subjects 707 
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PK assessments
Blood, urine and faecal samples were collected for the measurement of cadazolid concentrations. In the SAD study, blood samples were collected on day 1 prior to the dose and at 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 96 and 120 h post-dose. A similar schedule of blood sampling was applied in the MAD study on day 1 (first 12 h post-dose only) and on day 10 (up to 72 h post-dose), whereas between day 2 and day 9, blood was sampled once daily (in the morning, shortly before dosing). Within 30 min of collection, blood samples were centrifuged and plasma was transferred into new polypropylene tubes. All plasma samples were stored in an upright position at a maximum temperature of -208C.
In addition, the presence of cadazolid metabolites was evaluated in pooled plasma samples from the 300 mg and 3000 mg dose groups of the MAD study, sampled on day 10.
Urine samples were collected into polyethylene containers over the following time intervals: pre-dose, 0 -12, 12-24, 24-48, 48-72, 72 -96 and 96-120 h post-dose for the SAD study and 0 -12 h post-dose on day 1 and day 10 for the MAD study. During each collection period, the contents were stored in a refrigerator at 2 -88C. At the end of each collection period, the volume was recorded and urine aliquots were stored at approximately -208C.
Faecal samples were collected between day 1 and day 6 in the SAD study and between day 6 and day 9 in the MAD study in separate pre-weighed polypropylene boxes and stored within 2 h of collection at approximately -208C.
Bioanalysis
Validated HPLC coupled to tandem mass spectrometry (HPLC -MS/MS) assays specific for the measurement of unchanged cadazolid in human plasma, urine and faeces were used.
The analytical methods were validated at Inovalab AG (Reinach, Switzerland). The guideline Guidance for Industry: Bioanalytical Method Validation (May 2001) 16 was followed to conduct the validation of the analytical method. The inter-assay accuracy ranges for quality control samples in plasma, urine and faeces were 89.7%-99.6%, 93.6%-101.3% and 93.9%-109.3%, respectively. The inter-assay precision (CV%) for quality control samples in plasma, urine and faeces were ≤7.6%, 12.5% and 8.5%, respectively. No significant interference of matrix with the analyte was determined in human plasma, urine or faeces. Stability was confirmed up to 12 months storage in plasma, urine and faeces.
The MS/MS analysis was performed using a triple quadrupole system (MDS Sciex, API 4000, Applied Biosystems, Rotkreuz, Switzerland) in the positive ionization mode for the measurement of cadazolid in plasma and in urine, and in the negative ionization mode for the analysis in faeces.
For the analysis of cadazolid in plasma and urine, the thawed samples were mixed with a solution of tetra-deuterated cadazolid (internal standard) and were centrifuged for 5 min at a relative centrifugal force of 4230 and a temperature of 88C.
For the analysis of cadazolid in faeces, the workup of samples was carried out using liquid-liquid extraction [five extraction steps using dichloromethane:methanol (9: 1)], after dispersion in water and addition of the internal standard.
An aliquot of the worked-up sample (plasma, urine or faeces) was injected and loaded to the HPLC trapping column (Phenomenex Gemini C18, Schlieren, Switzerland) and the analyte was then eluted to the main column (Phenomenex Synergy 4u MAX-RP, Schlieren, Switzerland) for separation and detection by MS/MS. A gradient elution with the mobile phases A [water+formic acid (1000+1)] and B [acetonitrile+formic acid (1000+1)] was conducted.
The limit of quantification (LOQ) of the bioanalytical assays was set based on standard acceptability criteria of analyte:matrix peak ratios and assay precision and accuracy. The LOQs were 0.25 ng/mL, 1.00 ng/mL and 5.00 ng/g in plasma, urine and faeces, respectively.
In addition, two of the faeces samples collected within the SAD study (from subjects in the 3000 mg dose group) were processed through highspeed centrifugation (22000 g, for about 2 h) and ultrafiltration (molecular weight cut-off: 30 000). The fraction of cadazolid in the filtered supernatant was measured and compared with the concentration measured in the original sample.
PK and statistical analysis
Non-compartmental analysis of the individual plasma concentration -time profiles of cadazolid was performed using WinNonLin w 5.2 software (Pharsight, Mountain View, CA, USA) and the following PK variables were derived per subject: C max and T max (in the SAD study and on day 1 of the MAD study), C max,ss and T max,ss (on day 10, MAD study), AUC 0 -1 (in the SAD study), AUC 0 -t and t1 2 (in the SAD study and on day 10 of the MAD study) and AUC 0 -12 (0-12 h, on day 1 and day 10 of the MAD study).
AUC 0 -t was determined according to the linear trapezoidal rule using the measured concentration-time values above the LOQ. AUC 0 -1 was calculated by combining AUC 0 -t and AUC t -1 . AUC t -1 represented an extrapolated value obtained by C t /l z , where C t was the last plasma concentration measured above the LOQ and l z represented the elimination rate constant determined using log-linear regression analysis of the measured plasma concentrations of the terminal elimination phase. The t1 2 was calculated as follows: t1 2 ¼ln 2/l z . Dose proportionality was assessed across doses of cadazolid for C max , C max,ss and AUC values using the power model. 17 A point estimate and 90% CI were produced for the population mean slope. Approximate dose proportionality was established if the 90% CI for the slope was completely contained in the range 1 +log(0.5)/log(r), 1 +log(2)/log(r), where r¼high dose/low dose.
The effect of food on the PK of a 300 mg single cadazolid dose was evaluated using analysis of variance. Point estimates and 90% CI estimates of the differences between the treatments (fed and fasted) were derived. The final estimates represented the ratio of the generalized least squares mean of the test treatment to the generalized least squares mean of the reference treatment.
For T max , a Hodges -Lehmann-type point estimate of the median differences between the test and reference treatments was calculated, together with corresponding 90% CI.
In the MAD study, the accumulation index of cadazolid in plasma, between day 1 and day 10, was calculated as AUC 0 -12 (day 10)/AUC 0 -12 (day 1).
The individual cumulative concentrations and the overall excretion in urine and faeces relative to the total dose of cadazolid (SAD and MAD studies) were determined.
For calculating mean values, all values below the LOQ were set to zero. If .50% of the values at a given timepoint were below the LOQ, no mean value was derived. PK variables are reported as geometric means and 95% CI, except where differently stated. SAS w software, version 9.2 (SAS Institute, Cary, NC, USA) was used for the statistical analysis.
Results
Demographics and baseline characteristics
In the SAD study, a total of 40 healthy Caucasian male subjects were enrolled, of whom 30 received cadazolid and 10 received placebo. Thirty-nine subjects completed the study and one subject in the 100 mg group withdrew consent for personal reasons. The mean+SD age, weight and body mass index were 51.4+5.3 years, 82.5+8.7 kg and 25.9+2.3 kg/m 2 , respectively. In the MAD study, a total of 24 healthy Caucasian male subjects were enrolled, of whom 18 subjects received cadazolid and 6 subjects received placebo. All subjects completed the study. The Baldoni et al. 
Safety and tolerability
Cadazolid was well tolerated both in the SAD and the MAD study. No clinically relevant effects of treatment with cadazolid on the mean clinical laboratory parameters, ECG recordings or vital sign values were observed when comparing the values obtained during and at the end of the study with those obtained at baseline.
In the SAD study, 12 of the 40 subjects reported AEs: 8 subjects after administration of cadazolid and 4 subjects after administration of placebo. The most frequent AE was headache, reported by two subjects each within the 100 mg group, the 1000 mg group and the placebo group. One of the headache events was reported approximately 5 h after dosing and the remaining events between 8 and 22 h after dosing. Four subjects reported diarrhoea: one subject each within the 30 mg, 1000 mg and 3000 mg dose groups, and one in the placebo group.
One subject discontinued the study prematurely and 2 days after discharge from the study site reported a serious AE associated with alcoholic poisoning leading to hospitalization. The AE was considered non-treatment related by the investigator.
In the MAD study, 8 of the 24 subjects reported AEs: 7 subjects after administration of cadazolid and 1 subject after administration of placebo. The most frequently occurring AE was headache, reported by two subjects in the 300 mg group, three subjects in the 1000 mg group and one subject in the placebo group. Three headache events were reported within the first 2 h after dosing; the remaining events of headache were reported between 6 and 10 h after dosing.
One study drug-related event of decreased appetite was reported in the 300 mg dose group. Importantly, no events of diarrhoea were reported for any of the subjects within the MAD study.
Most of the reported events were of mild intensity and none of the subjects reported an AE of severe intensity. At the end of the studies, all AEs resolved without sequelae.
Plasma PK
The plasma PK variables measured in the SAD and MAD studies are reported in Tables 1 and 2 , respectively.
Following single oral administration of cadazolid under fasted conditions, plasma concentrations were generally low (Figure 2 ). Peak plasma concentrations were achieved within 2 h, with no concentrations .3.3 ng/mL, and at the lower dose levels were followed by a rapid decline. Cadazolid plasma concentrations were detected up to 8 h post-dose in the 30 mg, 100 mg and 300 mg dose groups, and the last sampling times at which at least 50% of subjects had detectable concentrations were 2, 4 and 6 h, respectively. After the 1000 mg dose, cadazolid plasma concentrations were detected in at least 50% of the subjects up to 8 h post-dose, with no detectable concentrations in any subject from 24 h post-dose. In the 3000 mg dose group, cadazolid concentrations were measured in at least 50% of the subjects up to 24 h postdose, and one subject had detectable concentrations up to 120 h post-dose (0.29 ng/mL). At doses ,300 mg no true terminal t1 2 could be determined owing to low plasma concentrations. At Cadazolid tolerability and pharmacokinetics in healthy subjects 709 JAC higher dose levels, t1
2 could be determined in four of the six subjects in the 300 mg group and in five and six subjects in the 1000 mg group and 3000 mg group, respectively. The geometric mean t1 2 was shorter in the 300 mg group and in the 1000 mg group than Figure 2 . Arithmetic mean and SD (n¼6) plasma concentration-time profiles of cadazolid (SAD study) following the oral administration of 30 mg, 100 mg, 300 mg, 1000 mg and 3000 mg single doses under fasted conditions (a) and a single 300 mg oral dose under fasted and fed conditions (b). Arithmetic mean and SD (n¼6) plasma concentrationtime profiles of cadazolid on day 10 following twice-daily administration of 300 mg, 1000 mg and 3000 mg doses (MAD study) (c).
at the highest dose of 3000 mg, with values of 2.85, 3.58 and 12.85 h, respectively.
Because of missing t1 2 values across doses, AUC 0 -t rather than AUC 0 -1 was used for comparison of exposure in the food effect and dose proportionality analysis.
Following single oral administration in the fed state, the absorption of cadazolid at 300 mg was delayed by approximately 2 h (Figure 2 and Table 1 ). Food increased the C max and AUC 0 -t by approximately 2.6-fold (geometric means from 0.73 to 1.87 ng/mL) and 5-fold (geometric means from 3.13 to 15.69 ng . h/mL), respectively. The 90% CI of the point estimates fed:fasted ratio for C max and AUC 0 -t were 2.03-3.20 and 2.96 -8.45, respectively. These results suggest that food influenced both the rate and extent of absorption.
Analysis of the data for dose proportionality showed that the 90% CI for the population mean slope was outside the calculated range of 0.85-1.15 for both C max (0.27 -0.42) and AUC 0 -t (0.54 -0.90), suggesting that there was a less than dose-proportional increase in both variables across the doses tested. For a 10-fold dose increase, the increase in C max was only 1.6-fold (between the 30 mg and 300 mg doses), 2.1-fold (between the 100 mg and 1000 mg doses) and 2.9-fold (between the 300 mg and 3000 mg doses). The increase in AUC 0 -t was 4.2-fold (between the 30 mg and 300 mg doses), 4.5-fold (between the 100 mg and 1000 mg doses) and 6.5-fold (between the 300 mg and 3000 mg doses).
Similarly to observations in the SAD study, on day 1 and day 10 of the MAD study, peak plasma concentrations were achieved within 2-3 h post-dose. No concentrations .3.6 ng/mL were observed on day 1 (within 12 h of the morning dose) or .6.9 ng/mL on day 10. The terminal t1 2 (after the last dose on day 10) ranged between 13.0 and 14.2 h across doses (Table 2 ) and was consistent with the value determined for the highest dose tested in the SAD study: 3000 mg.
The plasma concentration -time profiles of cadazolid after 10 days of twice-daily dosing at 300, 1000 and 3000 mg are displayed in Figure 2 . Figure 3 shows individual and mean (95% CI) trough plasma concentrations (mornings) from day 3 to day 10. There is no difference across days, and steady state is thus likely to be achieved between day 3 and day 4 in all dose groups for the tested twicedaily regimens. The 90% CIs for the ratio of mean trough plasma concentrations on day 8 and the mean trough plasma concentrations on days 9 and 10 were outside the upper bound of the 80% -125% limit in all dose groups, and no statistically relevant conclusions about the achievement of steady state could thus be drawn.
The 90% CI for the population slope across doses for C max and AUC 0 -12 (day 1) were 0.24-0.56 and 0.11-0.52, respectively, and for C max,ss and AUC 0 -12 (day 10) were 0.08-0.43 and 0.10-0.44, respectively. Those values were outside and to the left of the critical range of 1+ log(0.5)/log(r), 1+log(2)/log(r), where r¼3000 mg dose/300 mg dose (i.e. 0.70-1.30), suggesting that there was a less than dose-proportional increase in cadazolid exposure. For a 10-fold dose increase (between 300 mg and 3000 mg), the increases in C max and AUC 0 -12 were 2.5-fold and 2.1-fold, respectively, on day 1 and 1.8-fold and 1.9-fold, respectively, on day 10.
The rate of absorption remained constant across doses and days, as no statistically significant differences in T max (Wilcoxon t-test Cadazolid tolerability and pharmacokinetics in healthy subjects P.0.05) were obtained. The accumulation of cadazolid observed in plasma on day 10 (geometric means) ranged between 1.7-fold and 2.7-fold, with no dose-dependent pattern (Table 2) . There was no evidence of any metabolites or degradation products in plasma samples obtained following 10 days of twice-daily dosing, either in the 300 mg group or the 3000 mg group. CL/F (where F stands for fraction of dose absorbed into systemic circulation) and V/F from the SAD study and CL ss /F and V ss /F from the MAD study (day 10) are reported in Tables 1 and 2 , respectively. For the 3000 mg dose groups, the values of CL ss /F and V ss /F are of the same order of magnitude as CL/F and V/F observed in the SAD study. For the 300 mg and 1000 mg dose groups, CL ss /F was approximately 0.5-fold CL/F and the V ss /F was 2-fold V/F.
Urinary and faecal excretion
The urinary excretion of unchanged cadazolid ranged between 0.001% and 0.012% of the administered dose in the SAD study and between 0.001% and 0.015% in the MAD study. The majority of the drug was recovered in the faeces. The arithmetic mean of the percentage of the dose of cadazolid recovered unchanged in the faeces after single oral doses was 86.1% in the 30 mg group and 81.0% in the 3000 mg group (Table 3) . Cumulative excretiontime profiles showed high heterogeneity in time profiles of cadazolid excretion. In most subjects, the highest excretion of cadazolid in faeces was observed at times .24 h and reached a plateau between 48 and 72 h post-dose, especially at the higher dose level (Figure 4) .
In the MAD study, faeces samples were collected over 96 h between day 6 and day 10 (pre-dose). The mean cumulative faecal recovery of unchanged cadazolid, calculated as the total amount of cadazolid measured normalized by the daily cadazolid dose, ranged between 86.9% and 93.5% (Table 3) .
The peak concentrations of cadazolid in faeces samples achieved geometric means (95% CI) of 11.18 mg/g (8.67-14.43) in the 3000 mg dose group of the SAD study. Following ultracentrifugation Baldoni et al.
and ultrafiltration in two of the faecal samples of subjects who had received a single dose of 3000 mg cadazolid approximately 1% of the total faecal concentration was measured in the filtered supernatant.
In the MAD study, average faecal concentrations calculated between day 6 and day 10 (geometric means) increased proportionally across doses, from approximately 2.4 mg/g to 9.4 mg/g, and to 27.7 mg/g (Table 3 ).
Discussion
Two phase I clinical studies were performed as single-centre, double-blind, placebo-controlled, ascending single or multiple oral dose studies and were aimed at characterizing the safety, tolerability and PK of cadazolid when administered orally to healthy male subjects. The SAD study was a first-in-human study and the starting single dose of 30 mg was deemed appropriate according to Guidance for Industry: Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers (July 2005). 18 The safety margins for the 30 mg and 3000 mg doses were 560-fold and 5.6-fold, respectively.
The most frequent AE reported both in the SAD and the MAD studies was headache. No consistent correlation could be identified between the occurrence of headache events and the PK of cadazolid in plasma. In addition, three subjects reported diarrhoea after having received cadazolid treatment in the SAD study. However, no events of diarrhoea were reported during the MAD study by any of the subjects, suggesting that this AE was not related to dose or duration of treatment. This is in accordance with the narrow antibacterial spectrum of cadazolid and the drug is therefore unlikely to affect the gut flora. 12 The overall exposure to cadazolid upon single and multiple oral dosing was very low. The majority of the compound was excreted unchanged in faeces, resulting in high concentrations at the site of action (colon). The low exposure to cadazolid after oral administration is consistent with observations in previous non-clinical studies, during which very low absorption of cadazolid was confirmed by quantitative whole-body autoradiography after oral doses of
The stability of cadazolid in the tested human matrices, together with the high recovery of unchanged cadazolid in faeces and the lack of metabolites or potential degradation products in plasma support the assertion that cadazolid is mostly retained in the gastrointestinal tract after oral administration. CL/F and V/F, as well as CL ss /F and V ss /F, were very high, have no physiological meaning and are consistent with a very low F for cadazolid after oral administration.
It is unlikely that the bioavailability of oral cadazolid could be affected by the integrity of the gut wall, which is impaired in patients with CDAD, based on non-clinical studies and on the physico-chemical characteristics of cadazolid. However, this should be explored in future clinical studies.
Although cadazolid plasma concentrations declined rapidly below the LOQ at the lower doses of the SAD study, the main PK characteristics of cadazolid in plasma could be determined at higher doses and in all dose groups after 10 days of twice-daily dosing in the MAD study, which best represents the clinical setting of cadazolid therapy.
The decline of cadazolid plasma concentrations in the 3000 mg dose group of the SAD study appeared biphasic, with a second and slower elimination phase of approximately 13 h (geometric mean), from approximately 8 h post-dose. The latter t1 2 may thus best represent the terminal elimination phase of cadazolid from the circulation and is consistent with the terminal t1 2 observed in all dose groups of the MAD study (geometric means ranging between 13 and 14 h) after the last dose on the morning of day 10.
For the lower doses in the SAD study, cadazolid was mostly not detectable in plasma from 8 to 12 h post-dose and thus only the first and faster phase was captured. Consequently, in those groups, t1 2 and AUC 0 -1 values derived by the PK analysis were underestimated.
When performing the analysis of dose proportionality and the effect of food, AUC 0 -t (determined according to the linear trapezoidal rule using the measured concentration -time values above the LOQ) rather than AUC 0 -1 was used. AUC 0 -t values, which are usually less accurate than AUC 0 -1 for estimating change in exposure across doses, still showed less than dose-proportional increases. Food was found to influence both the rate and extent of absorption of a single oral dose of cadazolid at 300 mg. The resulting plasma concentrations remained low and never exceeded the ng/mL level.
Within the multiple-dose regimen the accumulation of cadazolid in plasma on day 10 compared with day 1 was up to 2.7-fold and was not dose dependent. It is considered of no clinical concern since the total exposure achieved on day 10 remained low in all dose groups. Steady-state concentrations were achieved between day 3 and day 4, which is consistent with the values of t1 2 . Due to the high inter-subject variability, caused by the low concentration and the minimal absorption of cadazolid, a statistically sound conclusion on whether or not steady state was reached between day 8 and day 10 could not be drawn.
Urinary recovery was negligible and most of the study drug was recovered unchanged in the faeces within 72 h of single oral administration. Especially in the SAD study, the extent of recovery within the faecal samples showed high variability, and one subject within the 30 mg group had a cumulative excretion of only 32.1%. Judging from the excretion profile of this subject, the cumulative faecal excretion had not reached a plateau up to the last collection timepoint of 96 h. The low faecal recovery of the drug in this subject may be explained by slow bowel transit during the study period.
Approximately 1% of cadazolid could be extracted in the unbound form in faeces, as measured in two samples from subjects who received a 3000 mg single dose. The geometric mean peak levels of unbound cadazolid in faeces after a single 3000 mg dose could be estimated as approximately 0.112 mg/g. The latter value is .400-fold higher than the MIC 90 of cadazolid for C. difficile.
In conclusion, the results of these SAD and MAD studies show that cadazolid was well tolerated in healthy male subjects following doses of up to 3000 mg twice daily for 10 days. Systemic exposure was very low and the majority of compound was excreted unchanged in faeces, resulting in high concentrations at the site of action (colon). The results of these studies warrant the initiation of studies with cadazolid in CDAD patients. A phase II study (AC-061A201) to evaluate the efficacy of 10 days of treatment with three different doses of cadazolid in patients with C. difficile infection has recently been completed (http://clinicaltrials.gov/ show/NCT01222702).
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